Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

PURPOSE: CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Innocenti, Federico, Ou, Fang-Shu, Qu, Xueping, Zemla, Tyler J., Niedzwiecki, Donna, Tam, Rachel, Mahajan, Shilpi, Goldberg, Richard M., Bertagnolli, Monica M., Blanke, Charles D., Sanoff, Hanna, Atkins, James, Polite, Blasé, Venook, Alan P., Lenz, Heinz-Josef, Kabbarah, Omar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2019
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506418/
https://ncbi.nlm.nih.gov/pubmed/30865548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01798
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia